RxDoctor Payments Data

Nibu Mathew, MD

Internal Medicine · Alvin, TXNPI 1538231261

Payments from drug & device makers

$5,640in general payments, 2019–2025

Across 136 payments — averaging $41.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$714
  • Lilly USA, LLC$636
  • Johnson & Johnson$503
  • Boehringer Ingelheim$424
  • Amgen$399
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$5,57599%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,640 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$164,719
Medicare patients
208
Services billed
2,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$107,396
EliquisApixaban56$74,265
JardianceEmpagliflozin44$62,964
XareltoRivaroxaban32$42,797
TrulicityDulaglutide20$36,456
MounjaroTirzepatide16$28,788
Tresiba Flextouch U-200Insulin Degludec26$27,582
VascepaIcosapent Ethyl29$25,947
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$19,551
EntrestoSacubitril/Valsartan11$18,598
TradjentaLinagliptin11$12,718
Lagevrio (Eua)Molnupiravir11$8,596
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$7,762
Breo ElliptaFluticasone/Vilanterol11$6,514
Omega-3 Acid Ethyl Esters40$4,949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,536$107,39665 claims
Boehringer IngelheimJardiance, Tradjenta$424$75,68255 claims
PfizerEliquis, Paxlovid$69$75,63273 claims
Lilly USA, LLCTrulicity, Mounjaro$636$65,24436 claims
Johnson & JohnsonXarelto$503$42,79732 claims
GSKTrelegy Ellipta, Breo Ellipta$74$26,06625 claims
MerckLagevrio (Eua)$23$8,59611 claims
AbbVieSynthroid$67$2,29850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Alvin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →